Highmount Capital’s Celgene Corp CELG Stock Holding History

Highmount Capital’s Portfolio CELG Stock Details CELG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	$991K	Buy	8,565 +65	+0.8%	+$7.43K	0.25%	76
2015 Q1	$980K	Hold	8,500	–	–	0.24%	77
2014 Q4	$951K	Sell	8,500 -900	-10%	-$94.9K	0.23%	79
2014 Q3	$891K	Hold	9,400	–	–	0.22%	79
2014 Q2	$807K	Hold	9,400	–	–	0.19%	82
2014 Q1	$656K	Hold	9,400	–	–	0.15%	85
2013 Q4	$794K	Hold	9,400	–	–	0.18%	82
2013 Q3	$724K	Hold	9,400	–	–	0.18%	81
2013 Q2	$550K	Buy	+9,400	New	+$566K	0.14%	84

Other funds holding CELG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Highmount Capital's CELG Position: Q2 2015 in Review

Highmount Capital increased its Celgene Corp (CELG) stake by 0.76% in Q2 2015, buying an estimated $7.43K and bringing the position to 8,565 shares worth $991K. The position accounts for 0.25% of the portfolio, ranked #76.

Highmount Capital first reported a position in CELG in Q2 2013 and has held it in 9 quarters since. 1,201 funds tracked by Wall St. Rank hold CELG as of Q2 2015.

Highmount Capital held 8,565 shares of Celgene Corp worth $991K as of Q2 2015.
Highmount Capital bought 65 Celgene Corp shares in Q2 2015, an estimated $7.43K.
Celgene Corp made up 0.25% of Highmount Capital's portfolio in Q2 2015, its #76 holding.
Highmount Capital first reported a position in Celgene Corp in Q2 2013 and has held it in 9 quarters since.
1,201 funds tracked by Wall St. Rank held Celgene Corp as of Q2 2015.

Based on Highmount Capital's 13F filing for Q2 2015, filed 14 Aug 2015.